Cargando…
Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a disease that is associated with severe uncontrolled eosinophilic asthma. Eosinophils play an important pathogenic role in the development of both diseases. Benralizumab is an antieosinophilic monoclonal antibody that binds to the...
Autores principales: | Martínez-Rivera, Carlos, Garcia-Olivé, Ignasi, Urrutia-Royo, Blanca, Basagaña-Torrento, Maria, Rosell, Antoni, Abad, Jorge |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7819231/ https://www.ncbi.nlm.nih.gov/pubmed/33478439 http://dx.doi.org/10.1186/s12890-021-01397-7 |
Ejemplares similares
-
Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis
por: Koga, Yasuhiko, et al.
Publicado: (2022) -
Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023) -
Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis
por: Nanzer, Alexandra M., et al.
Publicado: (2020) -
Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis
por: Coppola, Angelo, et al.
Publicado: (2020) -
Emergence of extrathoracic manifestations of eosinophilic granulomatosis with polyangiitis during benralizumab treatment
por: Lim, Andy K H, et al.
Publicado: (2021)